Chimie physique générale Pharmacie galénique Chimie thérapeutique ,
Chimie thérapeutique Chimie thérapeutique ,
Hématologie -Génie Biologique, Chimie thérapeutique François DUPUIS.............................................. Pharmacologie Raphaël DUVAL .............................................. Microbiologie clinique ,
Biophysique-acoustique ,
Biophysique ,
Pharmacie galénique ASSISTANTS HOSPITALO-UNIVERSITAIRES, Biochimie et Biologie ,
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.25, issue.13, pp.1658-64, 2007. ,
DOI : 10.1200/JCO.2006.08.1620
Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma, Journal of Clinical Oncology, vol.25, issue.16, pp.2288-94, 2007. ,
DOI : 10.1200/JCO.2006.08.0705
Two Decades of Declining Cancer Mortality: Progress with Disparity, Annual Review of Public Health, vol.31, issue.1, pp.121-153, 2010. ,
DOI : 10.1146/annurev.publhealth.121208.131047
The cancer biomarker problem, Nature, vol.353, issue.7187, pp.548-52, 2008. ,
DOI : 10.1038/nm1107-1276b
The role of companion diagnostics in the development and use of mutation-targeted cancer therapies, Nature Biotechnology, vol.5, issue.8, 2006. ,
DOI : 10.1038/nrc1609
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.22, issue.16, pp.3238-3285, 2004. ,
DOI : 10.1200/JCO.2004.11.057
Estimating infra-national and national thyroid cancer incidence in France from cancer registries data and national hospital discharge database, European Journal of Epidemiology, vol.53, issue.4, pp.607-621, 2007. ,
DOI : 10.1038/bjc.1993.61
URL : https://hal.archives-ouvertes.fr/inserm-00341262
Quality assurance in pathology in colorectal cancer screening and diagnosis-European recommendations. Virchows Arch Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique HAS. Guide Affection Longue Durée -Cancer colorectal, pp.159-75, 2008. ,
Ann Oncol Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy, Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, pp.3677-83, 2009. ,
Colorectal cancer: prognostic molecular markers]):21-32. 15. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis, Gastroenterol Clin Biol. Cell, vol.28, issue.1, 1990. ,
Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options, British Journal of Cancer, vol.1, issue.1, 2007. ,
DOI : 10.1038/sj.bjc.6603847
Improving Resectability of Hepatic Colorectal Metastases: Expert Consensus Statement, Annals of Surgical Oncology, vol.12, issue.10, pp.1271-80, 2006. ,
DOI : 10.1007/BF02725339
Are there regional differences in the management of colon cancer in France? Eur J Cancer Prev, Bull Acad Natl Med, vol.187, issue.5, pp.815-837, 2003. ,
Référentiel Oncolor -http://www.oncolor.org. [cited; Available from, pp.31-38 ,
Hépato-gastro-entérologie -Editions Masson, 2009. ,
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest, J Clin Oncol, vol.37125, issue.961713, pp.1007-161670, 2007. ,
Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer, Annals of Surgical Oncology, vol.4, issue.1, 2006. ,
DOI : 10.1001/archsurg.1976.01360220026004
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study, Cancer Chemother Pharmacol. J Clin Oncol Feb, vol.6226, issue.14, pp.195-201689, 2008. ,
without cetuximab in the first-line treatment of metastatic colorectal cancer Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial, J Clin Oncol Feb Lancet, vol.1027, issue.31, pp.663-71, 2007. ,
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial, The Lancet, vol.370, issue.9582, pp.143-52, 2007. ,
DOI : 10.1016/S0140-6736(07)61087-3
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study, Annals of Oncology, vol.24, issue.3, pp.1042-1049, 2009. ,
DOI : 10.1200/JCO.2005.03.0106
The hallmarks of cancer. Cell, Jan, vol.7100, issue.1, pp.57-70, 2000. ,
Oncogenic kinase signalling, Nature. May, vol.17411, issue.6835, pp.355-65, 2001. ,
Novel agents on the horizon for cancer therapy. CA Cancer J Clin, Thérapies moléculaires ciblées -De la biologie aux applications, pp.111-148, 2008. ,
Comparing antibody and small-molecule therapies for cancer, Nature Reviews Cancer, vol.23, issue.Suppl. 2, pp.714-741, 2006. ,
DOI : 10.1038/nbt1068
The biology of VEGF and its receptors Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer, Nat Med. Mol Aspects Med, vol.235932, issue.862, pp.907-927, 2003. ,
Growing tumor vessels: More than one way to skin a cat ??? Implications for angiogenesis targeted cancer therapies, Molecular Aspects of Medicine, vol.32, issue.2 ,
DOI : 10.1016/j.mam.2011.04.001
Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials, Journal of Clinical Oncology, vol.27, issue.2, pp.71-87, 2009. ,
DOI : 10.1200/JCO.2008.17.7931
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer, J Clin Oncol J Clin Oncol, vol.2629, issue.12, pp.2013-2022, 2008. ,
Lessons from phase III clinical trials on anti-VEGF therapy for cancer, Nature Clinical Practice Oncology, vol.25, issue.1, pp.24-40, 2006. ,
DOI : 10.1016/j.urolonc.2004.01.011
How to integrate molecular targeted agents in the continuum of care, Annals of Oncology, vol.370, issue.9582, pp.134-143, 2010. ,
DOI : 10.1016/S0140-6736(07)61087-3
Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08, Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity, pp.11-17, 2011. ,
DOI : 10.1200/JCO.2010.30.0855
Tumor angiogenesis: recent progress and remaining challenges]. Bull Cancer, pp.1305-1315, 2010. ,
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy, Journal of Clinical Oncology, vol.20, issue.21, pp.4368-80, 2002. ,
DOI : 10.1200/JCO.2002.10.088
Toward improved outcomes in hepatocellular carcinoma: overcoming the challenges of an "orphan" tumor. Gastrointest Cancer Res Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with firstline chemotherapy and bevacizumab High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer, Ann Oncol Hum Pathol, vol.3, issue.2, pp.73-56, 2008. ,
Serum Vascular Endothelial Growth Factor/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer, Pancreas, vol.37, issue.2, pp.1835-43145, 2008. ,
DOI : 10.1097/MPA.0b013e318164548a
Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab [EGFR expression in colorectal cancer and role in tumorigenesis]. Bull Cancer, Cancer Biol Ther, vol.1192, issue.60, pp.732-741, 2005. ,
Targeting the epidermal growth factor receptor: a clinical reality, J Clin Oncol Sep, vol.1519, pp.41-45, 2001. ,
The challenge of metastatic colorectal cancer Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors, Clin Med Insights Oncol. J Clin Oncol. Am J Pathol, vol.427, issue.64, pp.55-601122, 1997. ,
Understanding resistance to EGFR inhibitors???impact on future treatment strategies, Nature Reviews Clinical Oncology, vol.6, issue.9, pp.493-507, 2010. ,
DOI : 10.1091/mbc.4.1.121
Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer, European Journal of Oncology Nursing, vol.14, issue.4, pp.337-386, 2010. ,
DOI : 10.1016/j.ejon.2010.03.004
Targeted biotherapies in digestive oncology: management of adverse effects] Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximabassociated acne-like eruption, Gastroenterol Clin Biol. J Clin Oncol, vol.3311625, issue.72734, pp.306-221827, 2007. ,
Meta-Analysis of Incidence and Risk of Hypomagnesemia with Cetuximab for Advanced Cancer, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, pp.459-65, 2010. ,
DOI : 10.1159/000321011
Prognostic versus predictive value of biomarkers in oncology Clinical trial designs for predictive marker validation in cancer treatment trials, Clin Pharmacol Ther Eur J Cancer. J Clin Oncol, vol.694423, issue.779, pp.89-95, 2001. ,
Statistical issues in identifying, validating, and using molecular markers in clinical trials. ESMO -Impakt Breast cancer conference, p.79, 2009. ,
Growth factors of the EGF family and their receptors]. Bull Cancer, Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands, pp.137-182, 2007. ,
: Directing Key Signaling Networks Throughout Life, Annual Review of Pharmacology and Toxicology, vol.44, issue.1, pp.1183-93195, 2004. ,
DOI : 10.1146/annurev.pharmtox.44.101802.121440
Thérapies ciblées en cancérologie: Libbey Eurotext; 2006. 83. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy, Trends Mol Med. Nat Rev Cancer, vol.134, issue.845, pp.527-34361, 2004. ,
Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncol Mechanisms of resistance to EGFR inhibitors, Targeted Oncology, vol.102, issue.861, pp.522-731, 2007. ,
Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer Clin Colorectal Cancer, of the type III epidermal growth factor receptor mutation in colorectal cancer, pp.214-222, 2006. ,
Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors On the nature of low-and high-affinity EGF receptors on living cells, J Cell Biol Proc Natl Acad Sci, vol.109103, issue.9015, pp.2495-5075735, 1989. ,
Highaffinity binding of epidermal growth factor (EGF) to EGF receptor is disrupted by overexpression of mutant dynamin (K44A) High-and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways, ):e15945. 93. Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signalling on the surface of living cells, pp.16639-42168, 1998. ,
EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment, Cancer Res Feb, vol.171, issue.3, pp.1103-1117, 2011. ,
DOI : 10.1158/0008-5472.can-10-2384
URL : http://cancerres.aacrjournals.org/content/canres/71/3/1103.full.pdf
Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival, British Journal of Cancer, vol.258, issue.2, pp.16-20, 2007. ,
DOI : 10.1006/excr.2000.4905
Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications, Discov Med, vol.10, issue.50, pp.44-51, 2010. ,
Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas, Cancer Res. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol. J Clin Oncol, vol.654724, issue.9925, pp.338-489, 2005. ,
Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer., Journal of Clinical Oncology, vol.11, issue.10, pp.1873-1881, 1993. ,
DOI : 10.1200/JCO.1993.11.10.1873
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy, European Journal of Cancer, vol.41, issue.3, 2005. ,
DOI : 10.1016/j.ejca.2004.10.014
Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival, Clin Cancer Res, vol.7, issue.7, pp.1850-1855, 2001. ,
Her signaling in pancreatic cancer, Expert Opinion on Biological Therapy, vol.24, issue.6, 2007. ,
DOI : 10.1001/jama.297.3.267
Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor???Positive Premenopausal Breast Cancer, Journal of Clinical Oncology, vol.25, issue.21, pp.3007-3021, 2007. ,
DOI : 10.1200/JCO.2006.08.9938
EGFR targeting of solid tumors. Cancer Control, pp.295-304, 2007. ,
The Prognostic Significance of Epidermal Growth Factor Receptor Expressionin Clear-Cell Renal Cell Carcinoma: A Call for Standardized Methods for Immunohistochemical Evaluation, Clinical Genitourinary Cancer, vol.5, issue.4, pp.264-70, 2007. ,
DOI : 10.3816/CGC.2007.n.002
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme, Journal of Neuro-Oncology, vol.63, issue.Suppl 7, pp.77-86, 2005. ,
DOI : 10.1200/JCO.2004.99.242
The role of HER1- HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res, pp.123-153, 2006. ,
Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease, Gynecologic Oncology, vol.106, issue.3, pp.513-533, 2007. ,
DOI : 10.1016/j.ygyno.2007.04.028
Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell, pp.669-72, 2002. ,
Multimodality imaging of the HER-kinase axis in cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.9, issue.Pt 11, pp.186-208, 2008. ,
DOI : 10.1259/bjr.75.suppl_9.750024
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics, Seminars in Cell & Developmental Biology, vol.21, issue.9, 2010. ,
DOI : 10.1016/j.semcdb.2010.08.007
The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2003. ,
DOI : 10.1016/S0014-4827(02)00099-X
EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments, Journal of Dermatological Science, vol.56, issue.3, pp.148-53, 2009. ,
DOI : 10.1016/j.jdermsci.2009.10.002
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene, pp.3654-60, 2007. ,
The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol Cell, pp.730-738, 2007. ,
Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks, Cell, vol.127, issue.3, pp.635-683, 2006. ,
DOI : 10.1016/j.cell.2006.09.026
Signalisation cellulaire et cancer, 2010. ,
DOI : 10.1007/978-2-8178-0028-8
PI3K/PTEN signaling in tumorigenesis and angiogenesis, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol.1784, issue.1, pp.19-65, 2009. ,
DOI : 10.1016/j.bbapap.2007.09.008
Targeting PI3K signalling in cancer: opportunities, challenges and limitations, Nature Reviews Cancer, vol.16, issue.8, pp.550-62, 2009. ,
DOI : 10.4161/cc.7.5.5485
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting, Adv Cancer Res, vol.94, pp.29-86, 2005. ,
DOI : 10.1016/S0065-230X(05)94002-5
Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy, FEBS Letters, vol.2, issue.12, pp.2699-706, 2010. ,
DOI : 10.1371/journal.pmed.0020313
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer, Journal of Clinical Oncology, vol.20, issue.3, pp.719-745, 2002. ,
DOI : 10.1200/JCO.20.3.719
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry, Journal of Clinical Oncology, vol.23, issue.9, pp.1803-1813, 2005. ,
DOI : 10.1200/JCO.2005.08.037
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, Journal of Clinical Oncology, vol.22, issue.7, pp.1201-1209, 2004. ,
DOI : 10.1200/JCO.2004.10.182
Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs, pp.855-862, 2006. ,
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res, pp.2205-2218, 2010. ,
Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer, Clinical and Translational Oncology, vol.26, issue.11, pp.737-784, 2009. ,
DOI : 10.1016/j.bbapap.2007.09.008
Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3, pp.374-383, 2008. ,
DOI : 10.1200/JCO.2007.12.5906
URL : https://hal.archives-ouvertes.fr/hal-00363737
Clinical biomarkers of kinase activity: examples from EGFR inhibition trials, Cancer and Metastasis Reviews, vol.23, issue.supplement, pp.387-402, 2008. ,
DOI : 10.1016/j.ijrobp.2006.10.038
Metastatic Colon Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5924-5954, 2009. ,
DOI : 10.1200/JCO.2008.21.6796
URL : https://hal.archives-ouvertes.fr/hal-00618089
What can the molecular pathologist offer for optimal decision making? Ann Oncol, pp.123-132, 2010. ,
Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials, Annals of Oncology, vol.8, issue.12, pp.1197-206, 1997. ,
DOI : 10.1023/A:1008209720526
2-amino-3-(4-isothiocyanatophenyl)propyl]-trans- (S,S)-cyclohexane-1,2 -diamine-pentaacetic acid (CHX-A''-DTPA) conjugated monoclonal antibody L8A4 against epidermal growth factor receptor variant III (EGFRvIII), 2010. ,
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer, British Journal of Cancer, vol.25, issue.12, pp.1765-72, 2010. ,
DOI : 10.4161/cc.6.9.4211
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res, pp.3329-3363, 2010. ,
Transformation Efficiency of RasQ61 Mutants Linked to Structural Features of the Switch Regions in the Presence of Raf, Structure, vol.15, issue.12, 2007. ,
DOI : 10.1016/j.str.2007.10.011
Oncogenic mutations as predictive factors in colorectal cancer, Oncogene, vol.15, issue.21, pp.3033-3076, 2010. ,
DOI : 10.1016/S0002-9440(10)65579-4
K-ras Mutations in Putative Preneoplastic Lesions in Human Colon, JNCI Journal of the National Cancer Institute, vol.85, issue.24, pp.2004-2011, 1993. ,
DOI : 10.1093/jnci/85.24.2004
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, 2006. ,
Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1626-1660, 2008. ,
DOI : 10.1200/JCO.2007.14.7116
Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti-Epidermal Growth Factor Receptor Antibody Therapies, Cancer Research, vol.67, issue.6, pp.2643-2651, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-4158
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Annals of Oncology, vol.90, issue.3, pp.508-523, 2008. ,
DOI : 10.1093/jnci/90.9.675
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy, British Journal of Cancer, vol.14, issue.8, pp.1166-1175, 2007. ,
DOI : 10.1093/jnci/92.3.205
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients, British Journal of Cancer, vol.24, issue.8, pp.1139-1184, 2007. ,
DOI : 10.1016/j.ctrv.2003.10.003
Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab, Journal of Clinical Oncology, vol.25, issue.22, pp.3230-3237, 2007. ,
DOI : 10.1200/JCO.2006.10.5437
A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1stline treatment for patients (pts) with metastatic colorectal cancer (mCRC): results according to KRAS and BRAF mutation status, Eur J Cancer, vol.7, p.345, 2009. ,
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomised phase II study, J Clin Oncol, vol.25172, 2007. ,
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer, The Lancet Oncology, vol.9, issue.10, pp.962-72, 2008. ,
DOI : 10.1016/S1470-2045(08)70206-7
Recurrent KRAS codon 146 mutations in human colorectal cancer, Cancer Biology & Therapy, vol.5, issue.8, pp.928-960, 2006. ,
DOI : 10.4161/cbt.5.8.3251
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, The Lancet Oncology, vol.11, issue.8, pp.753-62, 2010. ,
DOI : 10.1016/S1470-2045(10)70130-3
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer, British Journal of Cancer, vol.8, issue.4, pp.715-736, 2009. ,
DOI : 10.1038/onc.2008.335
Differential regulation and properties of MAPKs, Oncogene, vol.24, issue.22 ,
DOI : 10.1016/j.str.2006.04.006
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer, Targeted Oncology, vol.27, issue.30, pp.19-28, 2010. ,
DOI : 10.1007/s11523-010-0138-5
BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis, Molecular Biology Reports, vol.2, issue.4, pp.2219-2242, 2011. ,
DOI : 10.1038/35052073
The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway, Oncology, vol.77, issue.1, pp.57-68, 2009. ,
DOI : 10.1159/000258497
Clinical significance of BRAF mutations in colorectal cancer]. Bull Cancer, pp.1441-52, 2010. ,
Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer, JNCI Journal of the National Cancer Institute, vol.7, issue.11, pp.573-578, 2010. ,
DOI : 10.1056/NEJMra0707704
Response: Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer, JNCI Journal of the National Cancer Institute, vol.4, issue.10, pp.573-578, 2010. ,
DOI : 10.1371/journal.pone.0007287
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer, British Journal of Cancer, vol.62, issue.3, pp.465-72, 2009. ,
DOI : 10.1126/science.1145720
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer, Journal of Clinical Oncology, vol.28, issue.7, pp.1254-61, 2010. ,
DOI : 10.1200/JCO.2009.24.6116
Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells, Cancer Letters, vol.296, issue.2, pp.150-159, 2010. ,
DOI : 10.1016/j.canlet.2010.04.006
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies, Cancer Research, vol.69, issue.5, pp.1851-1858, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-2466
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell, pp.157-70, 2007. ,
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res, pp.4997-5000, 1997. ,
Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene, pp.1743-1751, 1998. ,
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression, Proceedings of the National Academy of Sciences, vol.94, issue.17, pp.5246-50, 1998. ,
DOI : 10.1073/pnas.94.17.9052
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma, Cancer Res, vol.57, issue.17, pp.3660-3663, 1997. ,
Alterations of the MMAC1/PTEN gene in lymphoid malignancies, Blood, vol.91, issue.11, pp.4388-90, 1998. ,
Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast, The American Journal of Pathology, vol.155, issue.4, pp.1253-60, 1999. ,
DOI : 10.1016/S0002-9440(10)65227-3
PTEN mutations are common in sporadic microsatellite stable colorectal cancer, Oncogene, vol.23, issue.2, 2004. ,
DOI : 10.1038/sj.onc.1207059
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, pp.117-144, 2004. ,
Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2???Overexpressing Locally Advanced Breast Cancers, Journal of Clinical Oncology, vol.29, issue.2, pp.166-73 ,
DOI : 10.1200/JCO.2009.27.7814
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members, Oncogene, vol.10, issue.28, pp.3944-56, 2008. ,
DOI : 10.4161/cbt.5.10.3226
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients, British Journal of Cancer, vol.57, issue.1, pp.83-92, 2008. ,
DOI : 10.1002/cncr.10945
Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wildtype KRAS mCRC patients. Clin Cancer Res, pp.5591-602, 2010. ,
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy, British Journal of Cancer, vol.97, issue.8, pp.1330-1335, 2009. ,
DOI : 10.1200/JCO.2005.04.096
Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.27, issue.30, pp.5068-74, 2009. ,
DOI : 10.1200/JCO.2008.21.3744
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor???Targeted Therapy in Metastatic Colorectal Cancer, JNCI: Journal of the National Cancer Institute, vol.27, issue.28, pp.1308-1332, 2009. ,
DOI : 10.1038/onc.2008.19
Immune Activation by Epidermal Growth Factor Receptor???Specific Monoclonal Antibody Therapy for Head and Neck Cancer, Archives of Otolaryngology???Head & Neck Surgery, vol.133, issue.12, pp.1277-81, 2007. ,
DOI : 10.1001/archotol.133.12.1277
Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?, Cancer Science, vol.24, issue.9, pp.2048-53, 2010. ,
DOI : 10.1111/j.1349-7006.2010.01621.x
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy, Clinical Cancer Research, vol.10, issue.2, pp.784-93, 2004. ,
DOI : 10.1158/1078-0432.CCR-1100-03
Molecular Determinants of Cetuximab Efficacy, Journal of Clinical Oncology, vol.23, issue.15, pp.3536-3580, 2005. ,
DOI : 10.1200/JCO.2005.09.100
Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab standard dose treatment (Everest) : pharmacokinetic, pharmacodynamic and efficacy data, Proc Am Soc Clin Oncol, vol.25, p.4037, 2007. ,
Common Side Effects of Anti-EGFR Therapy: Acneform Rash, Seminars in Oncology Nursing, vol.22, issue.1, pp.28-34, 2006. ,
DOI : 10.1016/j.soncn.2006.01.013
Biomarkers in Cancer Staging, Prognosis and Treatment Selection, Nature Reviews Cancer, vol.2, issue.Suppl. 8, pp.845-56, 2005. ,
DOI : 10.1016/S1471-4892(02)00185-6
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges, Journal of Clinical Oncology, vol.27, issue.24, pp.4027-4061, 2009. ,
DOI : 10.1200/JCO.2009.22.3701
Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients, Clinical Cancer Research, vol.11, issue.21, pp.7872-7880, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0605
Personalized Medicine and Proteomics:?? Lessons from Non-Small Cell Lung Cancer, Journal of Proteome Research, vol.6, issue.8, pp.2925-2960, 2007. ,
DOI : 10.1021/pr070046s
Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma, Clinical Cancer Research, vol.13, issue.3, pp.799-805, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-1654
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer, International Journal of Cancer, vol.67, issue.6, pp.1321-1352, 2010. ,
DOI : 10.1002/ijc.25152
Analyse en composantes principales, 2006. ,
Comprendre et utiliser les statistiques dans les sciences de la vie: Masson, 2005. ,
Principal component analysis, 2002. ,
Analyse des données et des panels de données: De Boeck Université, 1999. ,
Validation of a Phosphoprotein Array Assay for Characterization of Human Tyrosine Kinase Receptor Downstream Signaling in Breast Cancer, Clinical Chemistry, vol.55, issue.7, pp.1327-1363, 2009. ,
DOI : 10.1373/clinchem.2008.116632
Comparative Proteomic Analysis of Non-small-cell Lung Cancer and Normal Controls Using Serum Label-Free Quantitative Shotgun Technology, Lung, vol.120, issue.10, pp.255-61, 2008. ,
DOI : 10.1002/ijc.22041
Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays, Molecular Cancer Therapeutics, vol.7, issue.12, pp.3695-706, 2008. ,
DOI : 10.1158/1535-7163.MCT-08-0810
A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkers for macrophage maturation in the U937 cell line, PROTEOMICS, vol.4, issue.4, pp.1014-1042, 2004. ,
DOI : 10.1002/pmic.200300669
Analyse factorielle multiple appliquée aux variables qualitatives et aux données mixtes. Revue de Statistique Appliquée, pp.5-37, 2002. ,
Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model, Molecular Cancer Therapeutics, vol.7, issue.7, pp.1923-1953, 2008. ,
DOI : 10.1158/1535-7163.MCT-07-2140
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer, Breast Cancer Research, vol.28, issue.Suppl, p.76, 2010. ,
DOI : 10.1200/JCO.2009.26.1602
Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry, Breast Cancer Research, vol.22, issue.6, p.113, 2010. ,
DOI : 10.1038/modpathol.2009.117
Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability, PROTEOMICS - CLINICAL APPLICATIONS, vol.121, issue.8, pp.874-82, 2009. ,
DOI : 10.1016/S0002-9440(10)64472-0
Accurate, Reproducible, and Quantitative Measurement of Protein Analyte Concentrations in Fixed Tissue. College of American Pathologists Foundation's Futurescape conference, 2009. ,
The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients, British Journal of Cancer, vol.26, issue.10, pp.1519-1542, 2010. ,
DOI : 10.1016/j.humpath.2007.04.008
Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res, Nov, vol.151322, issue.1, pp.6545-6553, 2007. ,
Proteomic analysis of RCL2 paraffin-embedded tissues, J Cell Mol Med, vol.12, issue.5B, pp.2027-2063, 2008. ,
RCL2, a New Fixative, Preserves Morphology and Nucleic Acid Integrity in Paraffin-Embedded Breast Carcinoma and Microdissected Breast Tumor Cells, The Journal of Molecular Diagnostics, vol.8, issue.2, pp.157-69, 2006. ,
DOI : 10.2353/jmoldx.2006.050105
Rapid emergence of multimarker strategies in laboratory medicine, Biomarkers, vol.55, issue.6, pp.289-96, 2010. ,
DOI : 10.1002/hep.20506
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients, British Journal of Cancer, vol.9, issue.1, pp.145-52, 2009. ,
DOI : 10.1158/1078-0432.CCR-05-1492
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer, PLoS ONE, vol.92, issue.10, p.7287, 2009. ,
DOI : 10.1371/journal.pone.0007287.t005
Discovery and validation of protein biomarkers for lung cancer, Thèse, 2010. ,
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors, New England Journal of Medicine, vol.353, issue.19, pp.2012-2036, 2005. ,
DOI : 10.1056/NEJMoa051918
Interactome under construction, Nature, vol.464, issue.7325, 2010. ,
DOI : 10.1038/468851a
URL : http://www.nature.com/nature/journal/v468/n7325/pdf/468851a.pdf
Employing Systems Biology to Quantify Receptor Tyrosine Kinase Signaling in Time and Space Springer, 2010. ,
Signalling ballet in space and time, Nature Reviews Molecular Cell Biology, vol.3, issue.6, pp.414-440 ,
DOI : 10.1038/msb.2009.19
Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology, Personalized Medicine, vol.6, issue.1, pp.33-47, 2010. ,
DOI : 10.1002/sim.2825
Systematic review of statistical methods used in molecular marker studies in cancer, Cancer, vol.26, issue.8, pp.1862-1870, 2008. ,
DOI : 10.1155/2004/202031